TD Cowen initiated coverage of Septerna with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2024 | $38.00 | Overweight | Analyst |
| 11/19/2024 | Buy | TD Cowen | |
| 11/19/2024 | $43.00 | Overweight | Wells Fargo |
| 11/19/2024 | $50.00 | Overweight | Cantor Fitzgerald |
SC 13D - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
SC 13G - Septerna, Inc. (0001984086) (Subject)
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00
TD Cowen initiated coverage of Septerna with a rating of Buy
Wells Fargo initiated coverage of Septerna with a rating of Overweight and set a new price target of $43.00
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the Investors & Media section of the company's website at www.septerna.com and will be archived for 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery powered by i
Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic Diseases Phase 1 Clinical Trial Ongoing for SEP-786, Oral Small Molecule for Hypoparathyroidism, with Data Expected in Mid-2025 Well-Capitalized with Balance Sheet to Support a Planned Operating Runway into Second Half of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today reported financial results for the third quarter ended September 30, 2024 and provided a portfolio overview and busines
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna. The aggregate gross proceeds to Septerna from the IPO were $331.2 million, before deducting underwriting discounts and com
4 - Septerna, Inc. (0001984086) (Issuer)
4 - Septerna, Inc. (0001984086) (Issuer)
10-Q - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)
8-K - Septerna, Inc. (0001984086) (Filer)